Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14937281 | 1.00 | NAMPT (0.41) | NAMPTJAK2JAK3PTK2TP53 | |
| SCHEMBL14936913 | 0.90 | GPBAR1 (0.36) | TP53LMNA | |
| SCHEMBL14965693 | 0.89 | GPBAR1 (0.35) | TP53MAPT | |
| SCHEMBL14936640 | 0.85 | GPBAR1 (0.38) | — | |
| SCHEMBL14936642 | 0.85 | GPBAR1 (0.38) | — | |
| SCHEMBL14936621 | 0.85 | NAMPT (0.44) | NAMPTTP53THRBGAASMN1; SMN2 | |
| SCHEMBL14936453 | 0.84 | GPBAR1 (0.37) | GAAMAPT | |
| SCHEMBL14936454 | 0.84 | GPBAR1 (0.37) | GAAMAPT | |
| SCHEMBL1390947 | 0.81 | GPR119 (0.46) | NAMPTJAK2JAK3PTK2TP53 | |
| SCHEMBL363900 | 0.81 | GPR119 (0.46) | NAMPTJAK2JAK3PTK2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780330-B1 | 1-PYRIDAZINYL-HYDROXYIMINO- 3- PHENYL- PROPANES AS GPBAR1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-01-06 | — | — | EP | disclosed |
| US-9090565-B2 | 1-pyridazinyl-hydroxyimino-3-phenyl-propanes | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130123267-A1 | 1-PYRIDAZINYL-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123267-A1 | 1-PYRIDAZINYL-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, ADRB1, GPER1 | NAMPT 3359/4885JAK2 2891/4885JAK3 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.